UPDATED: Boehringer's Pradaxa fights to regain ground with new clot-fighting approval

Save

Boehringer Ingelheim, determined not to let clot-fighter Pradaxa be outdone by Bayer and Johnson & Johnson's Xarelto, has added a couple of new uses to the drug's label, snagging the FDA's okay to treat deep vein thrombrosis (DVT) and pulmonary embolism (PE) in some patients. But it still has a long way to go–and some safety concerns to dispel–before it can retake the anticoagulant throne.